|
Saturday, April 29
8:00am–11:00am
2120—Management of Childhood Hypertension:
Guidelines and Controversies
PAS/ASPN/IPHA Mini Course
Chairs: Steven R. Daniels, Cincinnati Children's Hospital
Medical Center, Cincinnati, OH; and Ronald J. Portman,
University of Texas Medical School, Houston, TX
Target Audience: General
pediatricians, emergency medicine physicians, hospitalists,
intensivists, nephrologists and cardiologists.
The 2004 NHLBI guidelines for
childhood hypertension answered many questions about how to
approach hypertensive children, but left others unanswered.
This mini course is designed to address some of the more
controversial aspects of managing hypertensive children, with
the hope of stimulating further discussion on the optimal
approach to these patients. Practical approaches to clinical
management will be emphasized.
-
Overview
Stephen R. Daniels, Cincinnati Children's Hospital Medical Center,
Cincinnati, OH
-
Overview of Treatment Guidelines
from the 4th Report
Bonita E. Falkner, Thomas Jefferson University, Philadelphia, PA
-
Management of Pre-hypertension:
Lifestyle Changes or Pharmacologic Treatment?
Shawna D. Nesbitt, University of Texas Southwestern Medical Center,
Dallas, TX
-
Choice of Agent for Children with
Primary Hypertension
Joseph T. Flynn, Children's Hospital at Montefiore, Bronx, NY
-
Treatment of Severe Hypertension
in Ambulatory and Inpatient Settings
Joshua Samuels, University of Texas, Houston, TX
-
Treatment of Hypertension in
Special Populations
Donald L. Batisky, Columbus Children's Hospital/The Ohio State
University College of Medicine, Columbus, OH
-
Discussion
Sponsored jointly by
the American Society of Pediatric Nephrology, the
International Pediatric Hypertension Association and the
Pediatric Academic Societies
9:45am–11:45am
2200A—Clinical Trials and Observational
Studies
ASPN Workshop
Chairs: Susan L. Furth, Johns Hopkins University,
Baltimore, MD; and Craig Wong, Children's Hospital of New
Mexico, Albuquerque, NM
Target Audience: Clinical
investigators and pediatric nephrologists.
This workshop will address
statistical, measurement, ethical and regulatory issues in
clinical research. We will discuss methodological issues in
randomized clinical trials when the sample size is limited, as
often occurs in pediatric studies. We will also address the
measurement of kidney function in large cohort studies.
Finally, we will have an extended discussion on the evolution
of the current regulatory system of clinical research in the
United States. This has evolved from concerns about ethical
issues and protection of subjects to concerns about protection
of the institution through compliance with inflexible
requirements. The session will end with suggestions on what
changes are needed and how to achieve them in the current
regulatory environment.
-
Introduction
Catherine Stehman-Breen, Amgen, Thousand Oaks, CA
-
Methodologic Issues in Clinical
Trials When Sample Size Is Limited
Tom Greene, The Cleveland Clinic, Cleveland, OH
-
Measurement of Glomerular
Filtration Rate in Large Cohort Studies: Design, Conduct
and Analysis
Alvaro Munoz, Bloomberg School of Public Health, Johns Hopkins
University, Baltimore, MD
-
The Dysregulation of Research
Norman Fost, University of Wisconsin Medical School, Madison, WI
Supported by an
unrestricted educational grant from the Kidney and Urology
Foundation of America, Inc. (KUFA)
11:45am–2:45pm
2424—Treatment of the Metabolic Syndrome in
Children and Adolescents
PAS Educational Workshop
Leader: J. Darrell Nesmith, Little Rock, AR; Co-leaders:
Alba Morales, Mohammad Ilyas, Lisa Lubsch
Target Audience: Trainees,
fellows, junior faculty, mid-level faculty, senior faculty,
and community practitioners.
The rise in pediatric obesity and
metabolic syndrome is well established. Less understood for
the pediatrician is the treatment of the metabolic syndrome.
In this workshop, we aim 1) to briefly discuss the
epidemiology of the metabolic syndrome in children and
adolescents, 2) to discuss non-pharmacologic and pharmacologic
treatment of the metabolic syndrome, and 3) to review a
stepped approach in treating adolescents with the metabolic
syndrome.
This workshop will be largely
case-based. Come prepared to devise treatment plans in a small
group setting. Participants are invited to bring their own
cases for discussion.
Objectives:
– Participants will learn the
epidemiology of the metabolic syndrome in children and
adolescents.
– Participants will become familiar with existing treatment
guidelines for components of the metabolic syndrome in
children and adolescents.
– Participants will identify gaps in the literature
regarding treatment guidelines of the metabolic syndrome in
children and adolescents.
– Participants will consider pharmacologic treatment options
of metabolic syndrome treatment based on the available
evidence.
12:00pm–1:00pm
2450A—Renal Pathology—Battle of the
Brains
ASPN Luncheon
Chairs: Patrick D. Walker, Nephropathology Associates,
Little Rock, AR; and Victoria F. Norwood, University of
Virginia Children's Medical Center, Charlottesville, VA
Target Audience: American Society
of Pediatric Nephrology members and trainees.
Interactive clinical renal
pathology conference for fellows and selected pediatric
nephrology and pathology faculty during which cases will be
presented for evaluation and spirited discussion. The
objectives are to stimulate interactions between fellows and
members of the society; encourage broad discussions of renal
pathology, pathophysiology and treatment conundrums; and
stimulate the development of potential research questions.
Space is limited.
-
Welcome on Behalf of ASPN
Victoria F. Norwood, University of Virginia Children's Medical Center,
Charlottesville, VA
-
Overview and Keys to the Game
Patrick D. Walker, Nephropathology Associates, Little Rock, AR
1:00pm–3:00pm
2625—Nephrology I
PAS/ASPN Platform Session
3:15pm–5:15pm
2730—Mechanisms of Hypertension in the
Molecular Era
PAS/ASPN/IPHA/LWPES Topic Symposium
Chairs: Bruce Z. Morgenstern, Phoenix Children's Hospital,
Phoenix, AZ; and Julie R. Ingelfinger, Massachusetts General
Hospital, Boston, MA
Target Audience: General
pediatricians, nephrologists, endocrinologists and
neonatologists.
Our understanding of the
pathophysiology of hypertension has been changing rapidly due
to advances in molecular biology, most notably the
identification of several single-gene defects that cause
hypertension. This session will update the audience on the
latest advances in our knowledge of molecular mechanisms of a
variety of forms of hypertension.
-
Role of Dopamine Receptors
Pedro A. Jose, Georgetown University Medical Center, Washington, DC
-
Perinatal Programming and the
Development of Hypertension
Lori Woods, Oregon Health & Science University, Portland, OR
-
Low Renin Hypertension in
Childhood
Maria I. New, Mount Sinai School of Medicine, New York, NY
-
WNK Kinases and Blood Pressure
Regulation
Richard Lifton, Yale University School of Medicine, New Haven, CT
Sponsored jointly by
the American Society of Pediatric Nephrology, the
International Pediatric Hypertension Association, the Lawson
Wilkins Pediatric Endocrine Society and the Pediatric Academic
Societies
5:15pm–6:00pm
2800—Clinical Pediatric Hypertension
PAS/ASPN/IPHA Poster Symposium
8:00pm–10:00pm
2980A—ASPN Member Reception
ASPN Dinner
-
Presenter—Research Trainee
Awards
Susan L. Furth, Johns Hopkins University, Baltimore, MD
-
ASPN
Trainee Basic Research Award Recipients
Janis
Dionne, British Columbia Children's Hospital, Vancouver,
CA
David Sullivan Hains, Children's Hospital, Columbus, OH
-
ASPN
Trainee Clinical Research Award Recipients
Karen
L McNiece, University of Texas-Houston Medical School,
Houston, TX
Mai Thanh-Thuy Nguyen, Cincinnati
Children's Hospital, Cincinnati, OH
Sunday, April 30
7:00am–8:00am
3050—Life as a Pediatric Nephrologist
PAS Meet the Professor
This session is intended to
provide trainees and junior faculty with insights about career
opportunities in pediatric nephrology and appropriate
preparation for these careers. Career opportunities, both
within and outside of academic departments, will be discussed.
Faculty tracks and the perspective of department chairs about
these tracks also will be addressed. Topics will include how
to choose the appropriate academic position for one’s
interests and talents, as well as balancing career objectives
with personal and family goals.
Thomas R. Welch, Professor and Chair, Department of Pediatrics, SUNY
Upstate Medical University, Syracuse, NY
8:00am–10:00am
3115A—Renal Pathology—It's Still Not Just
Little Adults
ASPN Symposium
Chairs: Sharon P. Andreoli, James Whitcomb Riley Hospital
for Children, Indiana University Medical Center, Indianapolis,
IN; and Patrick Walker, Nephropathology Associates
Target Audience: Nephrologists
and pathologists.
The pathologic features of the
kidney in pediatric kidney disease have unique features
compared to adult patients and, some kidney diseases are
solely observed in pediatric patients. This symposia will
address the unique pathologic features of congenital nephrotic
syndrome, MPGN, renal pathology in pediatric transplant
patients and will also propose a new taxonomy for the
podocytopathies.
-
Congenital Nephrotic
Syndrome—An Update
Stephen M. Bonsib, James Whitcomb Riley Hospital for Children, Indiana
University Medical Center, Indianapolis, IN
-
MPGN and Dense Deposit Disease
Patrick D. Walker, Nephropathology Associates, Little Rock, AR
-
Renal Pathology in Pediatric
Transplant Patients
Carole A. Vogler, Saint Louis University, St. Louis, MO
-
Toward a New Taxonomy for the
Podocytopathies
Laura Barisoni, New York University School of Medicine, New York, NY
10:15am–12:00pm
3350—APS Presidential Plenary and Awards
APS Presidential Plenary
Chair: David K. Stevenson, Stanford University School of
Medicine, Palo Alto, CA
*The Joseph W. St. Geme, Jr.
Leadership Award is presented by the Federation of Pediatric
Organizations on behalf of the Ambulatory Pediatric
Association, American Academy of Pediatrics, American Board of
Pediatrics, American Pediatric Society, Association of Medical
School Pediatric Department Chairmen, Association of Pediatric
Program Directors and Society for Pediatric Research.
-
2006 APS Presidential Address
David K. Stevenson, Harold K. Faber Professor of Pediatrics, Senior
Associate Dean for Academic Affairs, Stanford University
School of Medicine; Director, Charles B. and Ann L.
Johnson Center for Pregnancy and Newborn Services; Chief,
Division of Neonatal and Developmental Medicine, Lucile
Packard Children's Hospital at Stanford, Palo Alto, CA
-
New Member Outstanding Science
Award
-
Epithelial Branching and the Origins of Kidney Malformation
Norman D. Rosenblum, Professor of Paediatrics and Canada Research Chair
in Developmental Nephrology, Division of Nephrology &
Program in Developmental Biology, The Hospital for Sick
Children, Toronto, Ontario, Canada
-
54th Annual John Howland Award
Kurt Hirschhorn, Professor of Pediatrics, Human Genetics and Medicine,
Chairman Emeritus, Department of Pediatrics, Mount Sinai
School of Medicine, New York, NY
-
Introduction, John Howland
Awardee
Frederick J. Suchy, Herbert H. Lehman Professor of Pediatrics and
Chair, Department of Pediatrics, Mount Sinai School of
Medicine, New York, NY
-
Joseph W. St. Geme, Jr.
Leadership Award
Carol D. Berkowitz, Professor of Clinical Pediatrics David Geffen
School of Medicine at UCLA
12:00pm–1:30pm
3430A—ASPN
Business Meeting, Luncheon and Presidential Address
ASPN Luncheon
-
ASPN Presidential Address
Sandra L. Watkins, Children's Hospital and Regional Medical Center,
Seattle, WA
2:00pm–4:00pm
3728—Nephrology II
PAS/ASPN Original Science Abstracts -
Platform Session
4:15pm–6:15pm
3825A—Systemic Lupus: Implications of
Recent Developments for Management of Children with Lupus
Nephritis
ASPN Symposium
Chairs: Joseph T. Flynn, Montefiore Medical Center, Bronx,
NY; and James Jarvis, University of Oklahoma Health Sciences
Center, Oklahoma City, OK
Target Audience: Nephrologists
and rheumatologists.
Glomerulonephritis remains a
significant source of morbidity in children with SLE. However,
recent changes in renal pathology and immunosuppressive
regimens offer the potential for improved outcomes in affected
children. This session will highlight some of the recent
advances in the diagnosis and treatment of children with lupus
nephritis.
-
Overview
Joseph T. Flynn, Children's Hospital at Montefiore, Bronx, NY
-
Lupus Nephritis: The
Rheumatologist's View
James N. Jarvis, University of Oklahoma Health Sciences Center,
Oklahoma City, OK
-
Updated WHO Classification
System: Are There Implications for Therapy?
Glen S. Markowitz, Columbia University Medical Center, New York, NY
-
Application of Monoclonal
Antibodies in Therapy: Rituximab and Beyond
Sangeeta Sule, Johns Hopkins University, Baltimore, MD
-
Cyclophosphamide Versus
Mycophenolate as Initial Therapy for Class III and IV
Lupus Nephritis
Ana L. Paredes, Miami Children's Hospital, Miami, FL
Sponsored jointly by
the AAP Section on Rheumatology and the American Society of
Pediatric Nephrology
Monday, May 1
8:00am–10:00am
4110—Pediatric Fluids and Hyponatremia: Are
We Giving Too Much Water?
PAS/ASPN/LWPES Topic Symposium
Chairs: John W. Foreman, Duke University Medical Center,
Durham, NC; and D. Michael Foulds, University of Texas Health
Science Center at San Antonio, San Antonio, TX
Target Audience: Nephrologists,
general pediatricians, emergency room doctors, intensivists,
hospitalits, endocrinologists and anyone who administers IV
maintenance fluids.
In the 1950s, Holiday and Segar
devised formulae for calculating intravenous maintenance
fluids for infants and children who were unable to drink.
These formulae have been taught and used now for over 40 years
and have generally stood the test of time. However, several
recent investigators have challenged these formulae and argued
that they put children at risk of hyponatremia. Since Holiday
and Segar devised these formulae, new information has arisen,
such as the concept of non-osmotic stimulation of ADH release
in sick children and our ability to measure ADH levels in
plasma on a routine basis. Arieff and Ayus were the first to
point out that children and women are at particular risk for
developing hyponatremic encephalopathy. Moritz and Ayus have
subsequently argued that hypotonic parenteral fluid should not
be used unless there are ongoing free water losses or
hypernatremia. In addition to this new clinical data,
Verkman’s group has exciting data identifying molecular
mechanisms of cerebral edema, including after water
intoxication. Dr. Arieff will review who is at risk and why.
Dr. Verkman’s group has developed data regarding mechanisms
of cerebral edema in experimental animals. Dr. Moritz will
describe the new concepts of maintenance fluids. Dr. Friedman
will defend the current practice. At the end there will be
time for an exchange between the speakers and the audience on
the right fluid to use in today’s children.
-
Hyponatremic Encephalopathy:
Special Risk Factors for Children and Women
Allen I. Arieff, University of California San Francisco, San Francisco,
CA
-
Aquaporin 4 and Cerebral Edema
Alan S. Verkman, University of California San Francisco, San Francisco,
CA
-
0.9% Sodium Chloride: The New
Approach to Maintenance Fluids in Pediatrics
Michael L. Moritz, Children's Hospital of Pittsburgh, Pittsburgh, PA
-
Maintenance Therapy: Tried and
True
Aaron L. Friedman, Brown Medical School, Hasbro Children's Hospital,
Providence, RI
Sponsored jointly by
the AAP Section on Nephrology, the American Society of
Pediatric Nephrology, the Lawson Wilkins Pediatric Endocrine
Society and the Pediatric Academic Societies
10:15am–12:10pm
4300
SPR Presidential Plenary and Awards
Chair:
Philip W. Shaul, University of Texas Southwestern Medical
Center, Dallas, TX
-
Introduction
Philip
W. Shaul, University of Texas Southwestern Medical Center,
Dallas, TX
-
Award
Presentations
Student
Research Awards
House Officer Awards
Fellow’s Basic Research Awards
Fellow’s Clinical Research Awards
David G. Nathan Award in Hematology/Oncology
Japan Pediatric Society Fellow Awardees
Douglas K. Richardson Award for Perinatal and Pediatric
Healthcare Research
Richard D. Rowe Award in Perinatal Cardiology
-
Young
Investigator Award and Lecture
-
Maureen
Andrew Mentor Award and Lecture
-
E.
Mead Johnson Awards for Research in Pediatrics and
Lectures*
-
Presidential
Address
Philip
W. Shaul, University of Texas Southwestern Medical Center,
Dallas, TX
*The
E. Mead Johnson Awards are supported by an educational grant
from Mead Johnson Nutritionals
12:00pm–1:00pm
4400A—ASPN Awards
Luncheon
ASPN Presidential Plenary
1:00pm–2:45pm
4500 March
of Dimes Prize in Developmental Biology Lecture
Dr. Varshavsky is a pioneer in
the study of ubiquitin, a tiny protein that has a very big
job. Ubiquitin (from the Latin ubique meaning
"everywhere," the source of the word
"ubiquitous") is so named because it is essential to
nearly every major activity in the life cycle of cells,
including cell growth and division during embryo development,
DNA repair, programmed cell death, immune response, and the
nervous system. The ubiquitin system is the housekeeping
mechanism by which the cell maintains a proper and healthy
balance of proteins. Ubiquitin's role was unknown until the
1980s, when Dr. Varshavsky and colleagues elucidated it. This
discovery revolutionized our understanding of the control of
human cells, and ubiquitin quickly became one of the major
areas of study in genetics, developmental biology, cell
biology, and biochemistry. Today ubiquitin is a cornerstone of
medical research into the causes and treatments of birth
defects, neurodegenerative disease, infections, and cancer.
Dr. Varshavsky receives the 2006 March of Dimes Prize for
revealing and characterizing
the biological significance of the ubiquitin system in the
regulation of living cells.
-
Regulation
by Proteolysis: The
N-End Rule Pathway in Yeast and Mammals
Alexander
Varshavsky, Smits Professor of Cell Biology, California
Institute of Technology, Pasadena, CA
Presented
by the March of Dimes Birth Defects Foundation
3:00pm–5:00pm
4630A—Molecular Control of the Formation of
the Renal Collecting System
ASPN Symposium
Chairs: Lisa M. Satlin, Mount Sinai School of Medicine, New
York, NY; and Norman D. Rosenblum, The Hospital for Sick
Children, Toronto, Ontario, Canada
Target Audience: Clinicians,
clinician-scientists and scientists interested in development,
nephrology and human disease involving the urinary tract.
Kidney development depends on
embryonic processes which pattern the collecting system
consisting of the ureter, renal pelvis and calyces, and
collecting ducts. Disruption of these processes in humans
results in a spectrum of anomalies including vesicoureteral
reflux, malformations of the pelvis and calyces, a decreased
number of collecting ducts and cystic malformation of these
ducts. Presentations in this symposium will highlight newly
elucidated genetic mechanisms that control different aspects
of collecting system formation. Analyses of genetic mouse
models are demonstrating a critical role for Fibroblast Growth
Factor Receptors in controlling growth and branching of the
ureteric buds that give rise to collecting ducts. Recent
evidence reveals a critical role for HNF1b, a transcription
factor, in controlling collecting duct terminal
differentiation and cyst formation via mechanisms involving
PKDH1, the gene mutated in human autosomal recessive kidney
disease. New genetic approaches are being harnessed to define
molecular mechanisms that control formation of the
vesico-ureteric orifice. Together, these discoveries and
approaches are providing novel molecular insights into
developmental nephrology and human disease.
-
Overview
Norman D. Rosenblum, Professor of Paediatrics and Canada Research Chair
in Developmental Nephrology, Division of Nephrology &
Program in Developmental Biology, The Hospital for Sick
Children, Toronto, Ontario, Canada
-
Role of Fibroblast Growth Factor
Receptors in Kidney Development
Carlton M. Bates, Children's Hospital of Columbus, Columbus, OH
-
Transcriptional Control of the
Bradykinin B2 Receptor
Samir S. El-Dahr, Tulane University School of Medicine, New Orleans, LA
-
Roles of HNF-1beta in Kidney
Development and Disease
Peter Igarashi, University of Texas Southwestern School of Medicine,
Dallas, TX
-
Genes and VUR
Ali Gharavi, Columbia University, New York, NY
Tuesday, May 2
8:00am–10:00am
5110A—Inflammation in Uremic
Pathophysiology
ASPN Symposium
Chairs: H. William Schnaper, Northwestern University
Feinberg School of Medicine, Chicago, IL; and Robert H.K. Mak,
Oregon Health and Science University, Portland, OR
Target Audience: Pediatric
nephrologists and fellows, basic scientists, pathologists and
immunologists.
Recent evidence has strongly
suggested that the manifestations of uremia are caused in
large part by activation of inflammatory pathways. This
symposium will review the syndromic events that can be
attributed to uremic inflammation and include oxidant injury,
cytokine production and its end-organ effects on the body
tissues.
-
Oxidant Injury in ESRD
Jonathan Himmelfarb, Maine Medical Center, Portland, ME
-
MIA (Malnutrition, Inflammation,
Atherosclerosis) Syndrome in ESRD
Joel D. Kopple, Harbor-UCLA Medical Center, David Geffen School of
Medicine at UCLA, UCLA School of Public Health, Torrance,
CA
-
Leptin and Melanocortin Signaling
in Chronic Kidney Disease
Robert H.K. Mak, Oregon Health and Science University, Portland, OR
-
Molecular Pathophysiology of
Muscle Catabolism in Uremia: Effect of Acidosis and
Inflammation
William E. Mitch, Baylor College of Medicine, Houston, TX
Supported by an
unrestricted educational grant from Abbott
10:00am–12:00pm
5360A—Pay for Performance: The Pediatric
Perspective—Hemodialysis
ASPN Workshop
Chairs: Sandra L. Watkins, Children's Hospital and Regional
Medical Center, Seattle, WA; and Bradley A. Warady, Children's
Mercy Hospital and Clinics, Kansas City, MO
Target Audience: Nephrologists.
Quality patient care is of utmost
importance to pediatricians caring for children. Congress and
the Centers for Medicare and Medicaid are exploring models of
“Pay for Performance” in an effort to reward high quality
patient care and encourage ongoing quality improvement. This
workshop explores the latest research results that aid the
clinician in improving patient outcomes in hemodialysis,
reviews the data available linking performance measures and
outcomes and discusses the mechanisms for reimbursement.
-
Overview
Bradley A. Warady, Children's Mercy Hospital and Clinics, Kansas City,
MO
-
New Insights into Improved
Quality Care in Hemodialysis
Stuart L. Goldstein, Baylor College of Medicine/Texas Children's
Hospital, Houston, TX
-
Quality Measures for Pediatric
Hemodialysis—What Should They Be?
Barbara Fivush, Johns Hopkins University, Baltimore, MD
-
How Can a Pediatric Nephrologist
be Appropriately Compensated for Providing Quality
Hemodialysis Care?
Linda Upchurch, Baxter Healthcare Corporation, Fletcher, NC
-
Discussion
Sponsored jointly by
the North American Pediatric Renal Transplant Cooperative
Study (NAPRTCS) and the American Society of Pediatric
Nephrology
1:45pm–3:45pm
5720—Autosomal Recessive Polycystic Kidney
Disease (ARPKD): New Insights and Clinical Perspectives
PAS/ASPN/NASPGHAN Topic Symposium
Chairs: Philip Rosenthal, University of California, San
Francisco, San Francisco, CA; and Lisa M. Guay-Woodford,
University of Alabama at Birmingham, Birmingham, AL
Target Audience: Pediatricians,
pediatric nephrologists, pediatric gastroenterologists,
neonatalogists and developmental biologists.
ARPKD is a developmental disorder
of the kidneys and liver caused by mutations in the PKHD1
gene. Fibrocystin/polyductin, the protein encoded by PKHD1, is
expressed on the primary cilia of renal and bile duct
epithelial cells. Several lines of evidence indicate that the
PKHD1 transcriptional profile is complex with extensive splice
variants. While the function of these transcripts and the
polypeptides that they encode is not well understood, these
proteins seem to play critical roles in establishing and
maintaining the tubular architecture. This symposium will
discuss the complex transcriptional profile of PKHD1 and the
role of these gene products in renal as well as biliary
epithelia. Given that ARPKD has a high perinatal mortality due
to oligohydramnios and resultant respiratory insufficiency,
current concepts regarding the interplay between the
developing kidney, the placenta and the developing lung will
be discussed. Finally, a clinical perspective based on the
on-going NHGRI-sponsored natural history study will focus on
ARPKD-associated morbidities and disease progression.
-
Transcriptional Complexity of
PKHD1: Implications for Development and Disease
Pathogenesis
Gregory G. Germino, Johns Hopkins University, Baltimore, MD
-
Pathobiology of Biliary Epithelia
in ARPKD
Tatyana Masyuk, Mayo Clinic College of Medicine, Rochester, MN
-
Oligohydramnios: Current Concepts
and Implications for Pulmonary Development
F. Sessions Cole, Washington University School of Medicine, St. Louis
Children's Hospital, St. Louis, MO
-
Report on the NIH ARPKD/CHF
Natural History Study
Meral Gunay-Aygun, National Human Genome Research Institute (NHGRI),
Bethesda, MD
Sponsored jointly by
the American Society of Pediatric Nephrology; the North
American Society for Pediatric Gastroenterology, Hepatology
and Nutrition; and the Pediatric Academic Societies
|
